Table 2.

Baseline characteristics in aPLA2R-positive and -negative patients

aPLA2R+ (n=82)aPLA2R− (n=28)aPLA2R+/− (n=7)
Sex (male/female)61/2124/46/1
Age at diagnosis (yr)50±1651±1758±19
Serum creatinine (μmol/L)94 (51–320)97 (58–280)97 (70–187)
Serum albumin (g/L)23.0±5.521.9±7.518.0 (9–32)
Proteinuria (g/d)9.9 (3.6–37.9)10.5 (4.2–20.0)5.7 (4.2–17.6)
eGFR (ml/min per 1.73 m2)73±2775±2769±22
Interval Bx serum sample (mo)2 (−2 to 6)2 (0–6)0 (0–5)
  • There were no significant differences between groups. Data are mean ± SD or median (range). eGFR was calculated using the MDRD formula. aPLA2R+, patients positive in both IIFT and ELISA tests; aPLA2R−, patients negative in both tests (n=28); aPLA2R+/−, discrepancy in antibody status between the two tests (n=7); Bx, renal biopsy.